Filing Flows

Filing Flows › Technology › Quantum X Labs (QXL)

Quantum X Labs (QXL) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Quantum X Labs (QXL) Q2 2026 earnings results →

Q2 2026 Revenue down 21% year over year to $293K · 825¢ of every $1 of revenue kept as net profit · operating margin -476.1%

Quantum X Labs made $293K in Q2 2026 (-21% Y/Y): Search Segment $283K, Adjustments and Eliminations $10K. Operating margin -476.1%, net earnings $2.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.

Revenue$293K
Year over year-21%
Operating margin-476.1%
Net earnings$2.4M
Operating cash flow−$1.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $293K in Q2 2026, down 21% year over year. Search Segment was the largest line at 97% of revenue. Search Segment lost $71K year over year (down 20%), 92% of the total change.

Operating costs exceeded revenue by $1.4M, an operating margin of -476.1%. Total costs grew 21% against a revenue fall of 21%. The fastest-growing cost line was Research & development (+825%). Net earnings were $2.5M ($2.4M including minority interests, which bore $68K of losses). The effective tax rate was -4.0%. Non-operating items added $3.7M, 160% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was −$1.1M. Non-cash charges added back $228K of depreciation and amortization. Working capital and other items used $3.7M. Capital expenditures of $186K exceeded it, leaving free cash flow of −$1.2M.

Quarterly history

Quantum X Labs revenue by quarterQuantum X Labs revenue by quarter$3.3MQ4 2024$2.7MQ1 2025$370KQ2 2025$2.7MQ3 2025$293KQ2 2026
Quantum X Labs net earnings by quarterQuantum X Labs net earnings by quarter−$4.0MQ4 2024−$3.8MQ1 2025−$12.4MQ2 2025−$4.0MQ3 2025$2.4MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 13, 2026$293K-21%-476.1%$2.4M−$1.1M
Q3 202510-QNov 14, 2025$2.7M-57%-133.7%−$4.0M−$1.7M
Q2 202510-QAug 19, 2025$370K-95%n/m−$12.4M−$427K
Q1 202510-QMay 14, 2025$2.7M-73%-35.5%−$3.8M−$409K
Q4 202410-KMar 21, 2025$3.3M-79%-125.1%−$4.0M−$447K

Charts

Quantum X Labs: revenue growth, year over year and quarter over quarterQuantum X Labs: revenue growth, year over year and quarter over quarterY/YQ/Q-79%Q4 2024-73%-18%Q1 2025-95%-86%Q2 2025-57%+400%Q3 2025-21%-89%Q2 2026
Latest (Q2 2026): Y/Y -21%, Q/Q -89%.
Quantum X Labs: where the cash came from (+) and went (−), TTM to Q2 2026Quantum X Labs: where the cash came from (+) and went (−), TTM to Q2 2026Other financing$7.7MOperating cash flow−$4.1MNet borrowing (+) / repaid (−)−$2.8MCash drawn (+) / kept (−)−$322KOther investing−$276KNot reconciled−$147K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Quantum X Labs: profit against cash, quarter by quarterQuantum X Labs: profit against cash, quarter by quarterNet incomeOperating cash flow−$695K$534KQ3 2024−$4.0M−$447KQ4 2024−$3.8M−$409KQ1 2025−$12.4M−$427KQ2 2025−$4.0M−$1.7MQ3 2025−$600KQ4 2025−$605K−$604KQ1 2026$2.4M−$1.1MQ2 2026
Latest (Q2 2026): Net income $2.4M, Operating cash flow −$1.1M.
Quantum X Labs: diluted shares by fiscal year (split-adjusted)Quantum X Labs: diluted shares by fiscal year (split-adjusted)30MFY202030MFY202130MFY20227MFY20239MFY20248MFY2025
-71.7% since FY2020: buybacks shrank the count; earlier years scaled for the 2-for-1 split before FY2025.
Quantum X Labs in its industry: growth against margin (192 companies, SIC 7372)Quantum X Labs in its industry: growth against margin (192 companies, SIC 7372)revenue growth, year over year →↑ operating marginmedian +12%median 0%MSFTORCLCRMADBEXYZINTUNOWSHOPCRWVSNPSPLTRADSKElectronic Arts Inc.TEAMSSNCCDNSRBLXTWLOSNOWTTWOCRWDGENDDOGHUBSVEEVDOCUOKTANETMDBNTNXPTCTYLDBXUDTPAYCMBLYESTCPCTYZETARBRKACIWBSYGWREPATHPCORTDCOCTVFIGKVYOCOURBILLBOXCVLTDUOLSAILGTMMANHLIMEAPPFCCCYOUTTANBLKBSGTLBALRMTENBWKPRGSFRSHAPPNBANDNAVNBRZEQTWONTSKASANCXMVERXRPDSPSCBLFSLYVRNSQLYSFROGMQBBINTANCNOEVCMNABLVIAALKTAVPTSPTPDGDYNXPERAMPLDDDSKILCERTCCSICMRCMKTWHUCKCRNCPDFSWEAVSOUNINSEXZODHIIIVLiveperson IncAIMRDNMYPSUPLDKLTRBLZELAWDRTTFBBAIMAPSCCLDEXFYRDVTSSTIEGANNTWKRCATSNALFDCTSVCOMCHXAEYEZDGEADBTWFCFAISPDUOTIDNPDYNQUBTZSPCROCFATNAWRESMSIINLXBLINMSGMGEGSEGGMYSZCXAIGXAIPARAAITXBKYICYABAPCXSPAIDSNYEXYNIDAIATDSIVDAVPRBSKKYUMEWAIFFAUIDGlobal Arena Holding, Inc.ATHRVIDALIVGUPYYFNGRSVMBTransparentBusiness, Inc.SWMRAMSTTransit Pro Tech Inc.PXLWDNKCDPLSGYGYQXL (-21%, -100%)
Services-Prepackaged Software; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Sells to

About Quantum X Labs

Quantum X Labs Inc. (formerly known as Viewbix Inc.) (the “Company”) was incorporated in the State of Delaware on August 16, 1985, under a predecessor name, The InFerGene Company (“InFerGene Company”). On August 25, 1995, a wholly owned subsidiary of InFerGene Company merged with Zaxis International, Inc., an Ohio corporation, which following such merger, the surviving entity, InFerGene Company, changed its name to Zaxis International, Inc. In 2015, the Company changed its name to Emerald Medical Applications Corp., subsequent to which the Company, through its subsidiary, was engaged in the development of technology for use in detection of skin cancer. On January 29, 2018, the Company ceased its business operations in this field.

In its own words, from its 10-Q, filed Aug 13, 2026.

Quantum X Labs against its Services-Prepackaged Software peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -21% against the peers' median +14%. Operating margin: -476.1% against the peers' median 15.2%.

CompanyQuarterRevenueY/YOp. margin
QXL Quantum X LabsQ2 2026$293K-21%-476.1%
MSFT MicrosoftQ1 FY27$92.3B+19%49.8%
ORCL OracleQ1 FY27$19.3B+30%34.8%
CRM SalesforceQ2 FY27$11.3B+11%20.5%
ADBE AdobeQ3 FY26$6.8B+13%34.8%
XYZ BlockQ3 2026$6.7B+10%6.4%
INTU IntuitQ4 FY26$4.4B+14%10.9%
NOW ServiceNowQ3 2026$4.1B+20%9.4%
SHOP ShopifyQ3 2026$3.7B+32%15.2%

Source: Quantum X Labs 10-Q on SEC EDGAR · CIK 797542 · Services-Prepackaged Software

13F: who owns QXL and who is buying

Largest holders of QXL (13F)Largest holders of QXL (13F)Mmcap International Inc. SPC$2.1MBank Hapoalim BM$114KUBS Group AG$76KXTX Topco$66KMorgan Stanley$1K
Funds' net buying of QXL by quarter (13F)Funds' net buying of QXL by quarter (13F)$402K2025-06$57K2025-09−$22K2025-12−$1K2026-03$1.6M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on QXL

History

Every quarter: Q2 2026 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare QXL with

中文版:Quantum X Labs(QXL)财报

Español · Français